Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Chevron Seeks Expanded U.S. License to Boost Venezuelan Oil Exports Amid Sanctions Talks 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
LEIDEN, the Netherlands, April 07, 2016 -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that the Annual General Meeting of Shareholders will be held on Tuesday, June 21, 2016 at 16:00 CET, at the offices of Allen & Overy at Apollolaan 15, 1077 AB Amsterdam, the Netherlands.
All relevant documents and information for the meeting, including the notice and agenda, are or will be made available in the ‘Investor Relations’ section of ProQR’s website (www.proqr.com) under ‘Financial Information’. The documents will also be made available on the SEC's website at www.sec.gov.
A live webcast of the event will be accessible in the ‘Investor Relations’ section of ProQR’s website under ‘Events and Presentations’.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber’s congenital amaurosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. Since 2012.
Contact:
Sariette Witte
Investor Relations
T: +1 213 261 8891
[email protected]
